» Articles » PMID: 12969975

Ultrastructural Study Shows Morphologic Features of Apoptosis and Para-apoptosis in Megakaryocytes from Patients with Idiopathic Thrombocytopenic Purpura

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2003 Sep 13
PMID 12969975
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

To investigate whether altered megakaryocyte morphology contributes to reduced platelet production in idiopathic thrombocytopenic purpura (ITP), ultrastructural analysis of megakaryocytes was performed in 11 ITP patients. Ultrastructural abnormalities compatible with (para-)apoptosis were present in 78% +/- 14% of ITP megakaryocytes, which could be reversed by in vivo treatment with prednisone and intravenous immunoglobulin. Immunohistochemistry of bone marrow biopsies of ITP patients with extensive apoptosis showed an increased number of megakaryocytes with activated caspase-3 compared with normal (28% +/- 4% versus 0%). No difference, however, was observed in the number of bone marrow megakaryocyte colony-forming units (ITP, 118 +/- 93/105 bone marrow cells; versus controls, 128 +/- 101/105 bone marrow cells; P =.7). To demonstrate that circulating antibodies might affect megakaryocytes, suspension cultures of CD34+ cells were performed with ITP or normal plasma. Morphology compatible with (para-)apoptosis could be induced in cultured megakaryocytes with ITP plasma (2 of 10 samples positive for antiplatelet autoantibodies). Finally, the plasma glycocalicin index, a parameter of platelet and megakaryocyte destruction, was increased in ITP (57 +/- 70 versus 0.7 +/- 0.2; P =.009) and correlated with the proportion of megakaryocytes showing (para-) apoptotic ultrastructure (P =.02; r = 0.7). In conclusion, most ITP megakaryocytes show ultrastructural features of (para-) apoptosis, probably due to action of factors present in ITP plasma.

Citing Articles

In the Era of Molecular Pathology, the Role of Morphological Changes in Megakaryocytes in Bone Marrow Aspiration in Cases of Isolated Thrombocytopenia.

Verma D, Singh L, Mandloi P, Ahirwar R Cureus. 2024; 16(11):e74336.

PMID: 39720389 PMC: 11667643. DOI: 10.7759/cureus.74336.


Desialylation and Apoptosis in Immune Thrombocytopenia: Implications for Pathogenesis and Treatment.

Zheng S, Perdomo J Curr Issues Mol Biol. 2024; 46(11):11942-11956.

PMID: 39590303 PMC: 11592706. DOI: 10.3390/cimb46110709.


Compound K Promotes Megakaryocytic Differentiation by NLRP3 Inflammasome Activation.

Hwang S, Park M, Koo A, Yoo E, Song S, Kim H Biomolecules. 2024; 14(10).

PMID: 39456190 PMC: 11506438. DOI: 10.3390/biom14101257.


Pathophysiology, Clinical Manifestations and Diagnosis of Immune Thrombocytopenia: Contextualization from a Historical Perspective.

Martinez-Carballeira D, Bernardo A, Caro A, Soto I, Gutierrez L Hematol Rep. 2024; 16(2):204-219.

PMID: 38651450 PMC: 11036214. DOI: 10.3390/hematolrep16020021.


Allogeneic platelet-rich plasma for knee osteoarthritis in patients with primary immune thrombocytopenia: A randomized clinical trial.

Zhu X, Zhao L, Riva N, Yu Z, Jiang M, Zhou F iScience. 2024; 27(5):109664.

PMID: 38646173 PMC: 11031822. DOI: 10.1016/j.isci.2024.109664.